Bizmoon
Grants & Loans
Regulations
Industries
Sign in
Learn more
Bizmoon

Product

  • Grants
  • Regulations
  • License checker
  • Guides
  • How it works
  • Pricing
  • Blog

Industries

  • Healthcare
  • Trade and Commerce
  • Transportation and Logistics
  • Energy and Utilities
  • Finance and Banking
  • Land and Natural Resources
  • Agriculture

Coverage

  • All grants
  • All regulations
  • Federal grants
  • Federal regulations

Company

  • Careers
  • Sign in
© 2026 BizmoonPrivacyTermsCredits
  1. Home
  2. Regulations
  3. Federal

Federal regulations

Agency
  • DOC253
  • SEC249
  • HHS221
  • DOT215
  • DOE178
  • FDA172
  • FERC159
  • DHS147
  • EPA105
  • FAA100
  • NOAA87
  • USDA61
  • DOJ58
  • DOL57
  • NIH56
  • Treasury51
  • SBA30
  • FCC26
  • HUD22
  • IRS18
  • CMS17
  • FTC5
  • Recency
    • Last 30 days
    • Last 7 days
    CMSRemove filter: CMSFDARemove filter: FDAClear all
    • Establishment Registration and Product Listing for Tobacco Products
      June 29, 2026

      FDA proposes requiring foreign tobacco product establishment owners and operators to register with the agency and list their products, extending current domestic-only registration requirements to close information gaps.

    • Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
      June 29, 2026

      The FDA seeks OMB approval for information collection procedures related to animal drug applications for minor uses and minor species under the Paperwork Reduction Act.

    • Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)
      June 29, 2026

      FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will hold a public meeting to review Capricor's biologics license application for Deramiocel, a cell therapy product, with public comment accepted via docket submission.

    • Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
      June 29, 2026

      FDA classifies medial knee implanted shock absorbers as Class II devices subject to special controls to ensure safety and effectiveness while reducing regulatory burden for manufacturers.

    • Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
      June 29, 2026

      FDA determines the regulatory review period for VYALEV human drug product patent extension purposes and publishes this notice as required by law.

    • La Ceiba Foods Latin Market Inc. Recalls Cottage Cheese Products Because of Possible Health Risk
      June 26, 2026

      La Ceiba Foods Latin Market Inc. recalls Requesón Salvadoreño and Requesón Mexicano cottage cheese products under La Colonia and Selectos Latinos brands due to possible Listeria monocytogenes contamination.

    • Total Nutrition Inc. Recalls Organic Moringa Products Following Supplier-Initiated Recall Due to Possible Health Risk
      June 26, 2026

      Total Nutrition Inc. recalls TNVitamins Organic Moringa capsules and powder due to possible Salmonella exposure in raw ingredient supplied by vendor; no illnesses reported.

    • Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
      June 26, 2026

      FDA revokes Emergency Use Authorizations for three COVID-19 diagnostic devices from Becton Dickinson, InBios International, and Roche Diagnostics upon manufacturer request.

    • Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
      June 26, 2026

      FDA classifies prognostic tests for preeclampsia development or progression as class II devices, requiring special controls to ensure safety and effectiveness while reducing regulatory burden for manufacturers.

    • Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms
      June 26, 2026

      FDA classifies computerized behavioral therapy devices for fibromyalgia treatment into class II, requiring special controls to ensure safety and effectiveness while reducing regulatory burdens for manufacturers.

    Page 1 of 19 (182 total)Next

    Track Federal regulations for your business

    Tell Bizmoon what your business does and we'll cut the Federal Register down to what actually matters.

    Action items + deadlines

    Every rule is broken into specific to-dos with calendar dates.

    Affected areas

    We tell you which parts of your business each rule actually touches.

    Plain-English summaries

    Healthcare draws more federal rulemaking than any other sector

    After healthcare come the capital-heavy sectors: trade, transportation, energy, and finance. If you operate in one of them, the volume of change is relentless.

    Federal rulemaking

    • Healthcare and life sciences
    • Trade and commerce
    • Transportation and aviation
    • Energy and utilities
    • Finance
    • Natural resources
    • Other

    Browse by agency

    • CMS
    • DHS
    • DOC
    • DOE
    • DOJ
    • DOL

    Browse by state

    • Alabama
    • Arizona
    • California
    • Colorado
    • Florida
    • Illinois

    No legal jargon. Read the impact in two sentences.

    Real-time alerts

    Email + dashboard pings the moment something changes.

    Get started free
  • DOT
  • EPA
  • FAA
  • FCC
  • FDA
  • FERC
  • FTC
  • HHS
  • HUD
  • IRS
  • NIH
  • NOAA
  • SBA
  • SEC
  • Treasury
  • USDA
  • Kentucky
  • Louisiana
  • Maryland
  • Massachusetts
  • Michigan
  • Minnesota
  • Missouri
  • New York
  • North Carolina
  • Ohio
  • Pennsylvania
  • South Carolina
  • Tennessee
  • Texas
  • Virginia
  • Washington
  • Wisconsin
  • Federal grants